Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Two distinct signalling pathways are involved in FGF2-stimulated proliferation of choriocapillary endothelial cells: A comparative study with VEGF

Abstract

In the retina, angiogenesis is an important component of normal physiological events such as embryonic vascular development. It is also involved in pathological processes including diabetic retinopathies and age-related macular degeneration, and tumour growth such as choroidal melanoma. Fibroblast growth factor (FGF) 2 and vascular endothelial cell growth factor (VEGF) are the two major angiogenic factors in the retina. We investigated the mechanism of proliferation and the regulation of the mitogenic properties of FGF2 and VEGF in cultures of chorocapillary endothelial cells (CEC). FGF2 is a strong mitogen for CEC and induced a 2.5-fold increase in cell proliferation after 4 days in culture in the absence of serum. In contrast, VEGF is a poor mitogen for CEC. FGF2, but not VEGF induces a large activation of MEK1, ERK1/2 and P90RSK during CEC proliferation. Pharmacological inhibition of Ras processing, and of MEK1 and ERK1/2 activation reduced only by 50% FGF2-induced cell proliferation, suggesting that there is another signalling pathway for CEC proliferation. Pharmacological inhibition of the PI 3-Kinase also inhibits by half FGF2-induced CEC proliferation. FGF2 stimulates the activation of the PI 3-K, P70S6K and Akt. Inhibition of both ERK1/2 and PI 3-K activities suppressed FGF2-induced CEC proliferation, demonstrating that CEC proliferation requires both ERKs and PI 3-K pathways. These data on the molecular mechanism and signalling may have important implications for providing more selective methods for anti-angiogenic and anti-tumoural therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9

Similar content being viewed by others

References

  • Alessi DR, Andjelkowic M, Cawdwell B . 1996 EMBO J. 15: 6541–6551

  • Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E . 1995 Nat. Med. 1: 1024–1028

  • Amin R, Puklin JE, Frank RN . 1994 Invest. Ophthalmol. Vis. Sci. 35: 3178–3188

  • Antonnetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW . 1999 J. Biol. Chem. 274: 23463–23467

  • Brian C, Duckworth BC, Cantley LC . 1997 J. Biol. Chem. 272: 27665–27670

  • Brown EJ, Albert MW, Shin TB . 1994 Nature 369: 756–758

  • Bryckaert M, Guillonneau X, Hecquet C, Courtois Y, Mascarelli F . 1999 Oncogene 18: 7584–7593

  • Buchkovich KJ, Ziff EB . 1994 Mol. Biol. Cell. 5: 1225–1241

  • Bullard LE, Penn JS . 2000 Ophthalmol. Vis. Sci. 41: S140

  • Campbell S, Khosravi-Fas R, Rossman KL, Clark GJ, Der CJ . 1998 Oncogene 17: 1395–1414

  • Chuang LM, Haussdorff SF, Myers MG . 1994 J. Biol. Chem. 269: 27645–27649

  • Cowley S, Paterson H, Kemp P, Marshal CJ . 1994 Cell 77: 841–852

  • Dalby KN, Morrice N, Cardwell FB, Avruch J, Chen P . 1998 J. Biol. Chem. 273: 1496–1505

  • D'Amore PA . 1994 Invest. Ophthalmol. Vis. Sci. 35: 3974–3979

  • Daum GI, Eisenmann-Tappe I, Fries HW, Troppmair J, Rapp UR . 1994 Trends Biochem. Sci. 19: 474–480

  • Dhanasekavan U, Premkumar Reddy E . 1998 Oncogene 17: 1447–1455

  • Enaida H, Ito T, Oshima Y, Sakamato T, Yago K, Kato K, Kochi H, Fukushima J . 1998 Med. Sci. 44: 43–52

  • Ferby IM, Waga I, Hoschino M, Kume K, Schimizu T . 1996 J. Biol. Chem. 271: 11684–11688

  • Folkman J, Klagsbrun M . 1987 Science 235: 442–447

  • Frank RN, Amin RH, Eliott D, Puklin JE, Abrams GW . 1996 Am. J. Ophthalmol. 122: 393–403

  • Gerber HP, McMurttrey A, Kowalski J, Yan M, Keut BA, Dixit V, Ferrara N . 1998 J. Biol. Chem. 273: 30336–30343

  • Guillonneau X, Tassin J, Berrou E, Bryckaert M, Courtois Y, Mascarelli F . 1996 J. Cell. Physiol. 166: 170–187

  • Guillonneau X, Regnier-Ricard F, Dupuis C, Courtois Y, Mascarelli F . 1998a Growth Factors. 15: 95–101

  • Guillonneau X, Bryckaert M, Longo-Launey C, Courtois Y, Mascarelli F . 1998b J. Biol. Chem. 273: 22367–22370

  • Guyer DR, Shabat AP, Green WR . 1994 In: Ryan SJ (ed). Retina 1 St Louis: Mosby p 1831

  • Hata Y, Rook SL, Aiello LP . 1999 Diabetes 48: 1145–1155

  • Hoffman S, Spee C, Murata T, Zha Cui J, Ryan SJ, Hinton DR . 1998 Graefe's Arch. Clin. Exp. Ophthalmol. 236: 779–784

  • Hu Q, Klippel A, Murlin AJ, Fantl WJ, Williams LT . 1995 Science 268: 100–102

  • Imai Y, Clemmins DR . 1999 Endocrinology 40: 4228–4235

  • Kanda S, Hodgkin MN, Woodfield RJ, Wakelman MJ, Thomas G, Claesson-Welsh L . 1997 J. Biol. Chem. 272: 23347–23353

  • Kent KC, Mii S, Harrington EO, Chang JD, Malette S, Ware JA . 1995 Cir. Res. 77: 231–238

  • Kerkhoff E, Rapp UR . 1998 Oncogene 17: 1457–1462

  • Lane HA, Fernandez A, Lamb NS, Thomas G . 1993 Nature 363: 170–172

  • Marumo T, Noll T, Schini-Kerth VB, Harley EA, Duhault J, Piper HM, Busse R . 1999 J. Vasc. Res. 36: 510–515

  • Marthe BM, Downward J . 1997 22: 355–358

  • Mounho BJ, Thrall BD . 1999 Toxicol. Appl. Pharmacol. 529: 125–133

  • O'Gorman DM, McKenna SC, Mc Gahon AJ, Knox KA, Colter TG . 2000 Leukemia. 14: 602–611

  • Pedram A, Razardi M, Levin ER . 1998 J. Biol. Chem. 273: 26722–26728

  • Qiu MS, Green SH . 1992 Neuron. 9: 705–717

  • Rikitake Y, Kawashima S, Yamashita T . 2000 Artheriosler. Tromb. Vasc. Biol. 20: 1006–1012

  • Ryan SJ, Stout JT, Dugel PU . 1994 In: Ryan SJ, (ed). Retina 2 St Louis: Mosby pp 1027–1048

  • Scheid MP, Poronoi V . 1996 J. Biol. Chem. 271: 18134–18135

  • Seghezzi G, Patel S, Ren CJ, Gualandris A, Pintucci G, Robbin I, Shapiro RL, Galloway AC, Rifkin DB, Mignatti P . 1998 J. Cell. Biol. 141: 1659–1673

  • Shen WY, Yu MJ, Barry CJ, Constable IJ, Rakocczy PE . 1998 Br. J. Ophthalmol. 82: 1063–1071

  • Spaks SH . 1973 Br. J. Ophthalmol. 57: 951–965

  • Stephens LR, Jackson TR, Hawkins PT . 1993 Biochem. Biophys. Acta. 1179: 27–75

  • Tazake K, Abe M, Sato Y . 2000 Jpn. J. Cancer Res. 90: 647–654

  • Tudan C, Jackson JK, Charlton L, Pelech SL, Sahl B, Burt HM . 1998 Biochem. J. 331: 531–537

  • Vinals F, Chambard JC, Pouyssegur J . 1999 J. Biol. Chem. 274: 26776–26782

  • Wada M, Ogata N, Otsuji T, Uyama M . 1999 Exp. Eye Res. 18: 203–213

  • Wang D, Yu X, Becker P . 1998 J. Biol. Chem. 273: 33027–33044

  • Weng QP, Andrali K, Klippel A, Kozlowsky MT, William LT, Avruch J . 1995 Proc. Natl. Acad. Sci. 92: 11696–11700

  • Wennström S, Downward J . 1999 Moll. Cell Biol. 19: 4279–4288

  • Wu LW, Mayo LD, Dunbar JD, Kessler KM, Baerwald MR, Jaffe EA, Wang D, Warren RS, Donner DB . 2000 J. Biol. Chem. 275: 5096–5103

  • Wu LW, Mayo LD, Dunhar JDJ . 2000 Biol. Chem. 257: 5096–5103

  • Yu Y, Sato JD . 1999 J. Cell. Physiol. 176: 235–246

Download references

Acknowledgements

We thank Dr Jean Plouet for his generous gift of VEGF. This work was supported by the Association pour la Recherche sur le Cancer (Contract number 9697, Frédéric Mascarelli) and the Association Claude Bernard (Anna Zubilewicz).

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zubilewicz, A., Hecquet, C., Jeanny, JC. et al. Two distinct signalling pathways are involved in FGF2-stimulated proliferation of choriocapillary endothelial cells: A comparative study with VEGF. Oncogene 20, 1403–1413 (2001). https://doi.org/10.1038/sj.onc.1204231

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204231

Keywords

This article is cited by

Search

Quick links